A Novel Running Wheel Mouse Model for Botulism and Its Use for the Evaluation of Postsymptom Antitoxin Efficacy.


Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
16 07 2021
Historique:
pubmed: 12 5 2021
medline: 10 8 2021
entrez: 11 5 2021
Statut: ppublish

Résumé

Antitoxin is currently the only approved therapy for botulinum intoxications. The efficacy of antitoxin preparations is evaluated in animals. However, while in practice antitoxin is administered to patients only after symptom onset, in most animal studies, it is tested in relation to time postintoxication. This may be attributed to difficulties in quantitating early botulism symptoms in animals. In the current study, a novel system based on high-resolution monitoring of mouse activity on a running wheel was developed to allow evaluation of postsymptom antitoxin efficacy. The system enables automatic and remote monitoring of 48 mice simultaneously. Based on the nocturnal activity patterns of individual naive mice, two criteria were defined as the onset of symptoms. Postsymptom treatment with a human-normalized dose of antitoxin was fully protective in mice exposed to 4 50% lethal doses (LD

Identifiants

pubmed: 33972251
pii: AAC.00421-21
doi: 10.1128/AAC.00421-21
pmc: PMC8284437
doi:

Substances chimiques

Antitoxins 0
Botulinum Toxins, Type A EC 3.4.24.69

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0042121

Références

N Engl J Med. 2006 Feb 2;354(5):462-71
pubmed: 16452558
Curr Top Med Chem. 2015;15(7):685-95
pubmed: 25751268
Pharmacol Res Perspect. 2018 Nov 22;6(6):e00446
pubmed: 30519475
Biologicals. 2017 Jul;48:24-27
pubmed: 28633975
MMWR Morb Mortal Wkly Rep. 2015 Jul 31;64(29):802-3
pubmed: 26225479
Toxicon. 2016 Feb;110:12-8
pubmed: 26615088
JAMA. 2001 Feb 28;285(8):1059-70
pubmed: 11209178
Neurosci Lett. 2016 Aug 3;627:216-21
pubmed: 27268041
J Infect Dis. 1992 Dec;166(6):1281-6
pubmed: 1431246
Clin Infect Dis. 2017 Dec 27;66(suppl_1):S43-S56
pubmed: 29293927
Muscle Nerve. 2011 Dec;44(6):930-6
pubmed: 22102464
Med Microbiol Immunol. 1975 Jul 2;161(3):203-10
pubmed: 1237779
Curr Top Med Chem. 2016;16(21):2330-49
pubmed: 27072693
Antimicrob Agents Chemother. 2018 Mar 27;62(4):
pubmed: 29437616
Acc Chem Res. 2019 Aug 20;52(8):2322-2331
pubmed: 31322847
J Hyg (Lond). 1939 Sep;39(5):574-80
pubmed: 20475518
Jpn J Med Sci Biol. 1970 Aug;23(4):282-5
pubmed: 4992617
J Bacteriol. 1956 Oct;72(4):455-60
pubmed: 13366946
Neurotoxicology. 2017 Mar;59:1-8
pubmed: 28043867
Jpn J Med Sci Biol. 1970 Oct;23(5):344-7
pubmed: 4993667
J Infect Dis. 1993 Feb;167(2):451-4
pubmed: 8421179
Microbiol Rev. 1980 Sep;44(3):419-48
pubmed: 6252433
Pharmacol Rev. 2017 Apr;69(2):200-235
pubmed: 28356439
J Infect Dis. 1969 Nov;120(5):534-8
pubmed: 5346536
Proc Biol Sci. 2014 Jul 7;281(1786):
pubmed: 24850923
PLoS One. 2014 Jan 22;9(1):e85517
pubmed: 24465585
Clin Infect Dis. 2005 Oct 15;41(8):1167-73
pubmed: 16163636
PLoS One. 2019 Sep 17;14(9):e0222670
pubmed: 31527885
Jpn J Med Sci Biol. 1963 Oct;16:310-1
pubmed: 14090797
J Appl Physiol (1985). 2018 Apr 1;124(4):923-929
pubmed: 29357507
Disaster Med Public Health Prep. 2007 Nov;1(2):122-34
pubmed: 18388640
Clin Infect Dis. 2006 Nov 15;43(10):1247-56
pubmed: 17051488
Jpn J Med Sci Biol. 1963 Oct;16:311-3
pubmed: 14090798
Neuroscience. 2006 May 12;139(2):629-37
pubmed: 16490322
PLoS One. 2014 Feb 27;9(2):e90252
pubmed: 24587301
Ann Intern Med. 1998 Aug 1;129(3):221-8
pubmed: 9696731
Toxicon. 2013 Jun 1;67:87-93
pubmed: 23201505
Jpn J Med Sci Biol. 1970 Jun;23(3):177-91
pubmed: 4989998
Toxicon. 2015 Dec 1;107(Pt A):37-42
pubmed: 26130522
Proc Natl Acad Sci U S A. 2010 Sep 21;107(38):16554-9
pubmed: 20823219
PLoS One. 2019 Jan 11;14(1):e0209019
pubmed: 30633746
Nat Rev Microbiol. 2014 Aug;12(8):535-49
pubmed: 24975322
Dis Model Mech. 2018 Sep 27;11(9):
pubmed: 30115749

Auteurs

Arieh Schwartz (A)

Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona, Israel.

Alon Ben David (A)

Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona, Israel.

Mordechai Hotoveli (M)

Department of Environmental Physics, Israel Institute for Biological Research, Ness Ziona, Israel.

Eyal Dor (E)

Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona, Israel.

Eran Diamant (E)

Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona, Israel.

Arik Vivyorka (A)

Division of Operations & Infrastructure, Israel Institute for Biological Research, Ness Ziona, Israel.

Osnat Rosen (O)

Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona, Israel.

Amram Torgeman (A)

Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona, Israel.

Ran Zichel (R)

Department of Biotechnology, Israel Institute for Biological Research, Ness Ziona, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH